Table 2.
PRGS ranging from 1 to 4 in 16 patients with peritoneal metastasis from pancreatic cancer who underwent at least one PIPAC treatment
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | |
| PRGS before PIPAC 1 (highest/mean) | 3/2.25 | 3/2 | 3/2.25 | 4/2.75 | 3/3 | 1/1 |
| PRGS before PIPAC 2 (highest/mean) | 2/1.25 | 2/2 | 3/1.75 | 3/2.25 | 2/2 | |
| Histological regression | + | U | + | + | + | |
| PRGS before PIPAC 3 (highest/mean) | 2/1.25 | 3/1.75 | 2/1.5 | 3/2 | ||
| Histological regression | U | + | + | – | ||
| PRGS before PIPAC 4 (highest/mean) | 2/1.75 | 3/2 | 3/2.67 | |||
| Histological regression | – | – | – | |||
| PRGS before PIPAC 5 (highest/mean) | 3/2.5 | 3/2.33 | ||||
| Histological regression | – | + |
| Patient 7 | Patient 8 | Patient 9 | Patient 10 | Patient 11 | Patient 12 | |
| PRGS before PIPAC 1 (highest/mean) | 1/1 | 3/3 | 1/1 | 3/2.25 | 2/1.33 | 1/1 |
| PRGS before PIPAC 2 (highest/mean) | 1/1 | 3/2 | 1/1 | 2/1,5 | ||
| Histological response | U | + | + | – | ||
| PRGS before PIPAC 3 (highest/mean) | 1/1 | 1/1 | ||||
| Histological response | U | + | ||||
| PRGS before PIPAC 4 (highest/mean) | 1/1 | 3/2.66 | ||||
| Histological response | U | – | ||||
| PRGS before PIPAC 5 (highest/mean) | 1/1 | |||||
| Histological response | U | |||||
| PRGS before PIPAC 6 (highest/mean) | 1/1 | |||||
| Histological response | U |
| Patient 13 | Patient 14 | Patient 15 | Patient 16 | |
| PRGS before PIPAC 1 (highest/mean) | 1/1 | 1/1 | 3/2 | 3/3 |
| PRGS before PIPAC 2 (highest/mean) | 1/1 | 1/1 | 3/2.33 | 2/2 |
| Histological response | U | U | – | + |
– indicates histological progression (according to mean PRGS); + indicates histological regression (according to mean PRGS).
PIPAC, Pressurised IntraPeritoneal Aerosol Chemotherapy; PRGS, Peritoneal Regression Grading Score; U, unchanged mean Peritoneal Regression Grading Score.